EBIT at other companies
Other financials
Where this comes from
Calculated from CytomX Therapeutics’s reported figures.
Plus components not separately reported this period.
The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about CytomX Therapeutics's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CytomX Therapeutics's EBIT?
- CytomX Therapeutics (CTMX) reported EBIT of -$19.67M in Q1 2026.
- How has CytomX Therapeutics's EBIT changed year-over-year?
- CytomX Therapeutics's EBIT decreased by 187.0% year-over-year, from $22.62M to -$19.67M.
- What is the long-term trend for CytomX Therapeutics's EBIT?
- Over 4 years (2021 to 2025), CytomX Therapeutics's EBIT has grown at a -33.7% compound annual growth rate (CAGR), from -$116.04M to -$22.37M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.